

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



国药集团
SINOPHARM

國藥控股股份有限公司 SINOPHARM GROUP CO. LTD.*

*(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)
(Stock Code: 01099)*

ANNOUNCEMENT PRINCIPAL FINANCIAL DATA OF SINOPHARM (CNCM LTD) FOR THE THREE MONTHS ENDED 31 MARCH 2018

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the overseas regulatory announcement of Sinopharm Group Co. Ltd. (the “**Company**”) dated 26 April 2018 (the “**Announcement**”) in relation to the first quarterly report for the three months ended 31 March 2018 of China National Medicines Corporation Ltd. (“**SINOPHARM (CNCM LTD)**”), a subsidiary of the Company and whose A shares are listed on the Shanghai Stock Exchange (stock code: 600511).

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited financial data of SINOPHARM (CNCM LTD) for the three months ended 31 March 2018 as set out in the Announcement.

PRINCIPAL FINANCIAL DATA OF SINOPHARM (CNCMLTD)

*Unit: Yuan
Currency: RMB*

	As at the end of this reporting period	As at the end of last year		Increase/decrease at the end of this reporting period as compared with last year-end (%)
		After adjustment	Before adjustment	
Total assets	20,522,240,630.52	20,165,954,616.27	20,165,954,616.27	1.77
Net assets attributable to shareholders of listed company	8,435,563,558.96	8,181,194,100.38	3.11	3.11
	From the beginning of the year to the end of the reporting period	From the beginning of last year to the end of the same period of the last year		Increase/decrease as compared with the same period of last year (%)
		After adjustment	Before adjustment	
Net cash flow arising from operating activities	29,834,236.21	-319,374,760.01	74,606,127.95	N/A
	From the beginning of the year to the end of the reporting period	From the beginning of last year to the end of the same period of the last year		Increase/decrease as compared with the same period of last year (%)
		After adjustment	Before adjustment	
Operating income	9,129,920,236.31	8,761,867,869.50	3,568,003,584.79	4.20
Net profit attributable to shareholders of the listed company	254,825,276.77	233,436,846.23	141,418,626.70	9.16
Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses	253,658,691.33	140,163,764.64	140,163,764.64	80.97
Weighted average ROE (%)	3.07	3.91	3.94	decreased by 0.84 ppts
Basic earnings per share (RMB/Share)	0.3323	0.3171	0.2954	4.79
Diluted earnings per share (RMB/Share)	0.3323	0.3171	0.2954	4.79

Explanation: The reason for the relatively significant change in the net profit attributable to the shareholders of listed company after deducting non-recurring gains and losses: the data of the combined enterprise under same control for the same period of last year is retrospective adjustment data, and in accordance with the accounting standards, the net profit or loss generated shall be classified in non-recurring gains and losses. After the formal combination carried out this period, the net profit or loss generated shall be classified in recurring gains and losses.

By order of the Board
Sinopharm Group Co. Ltd.
Li Zhiming
Chairman

Shanghai, the PRC
26 April 2018

As at the date of this announcement, the executive directors of the Company are Mr. Li Zhiming and Mr. Liu Yong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. She Lulin, Mr. Wang Qunbin, Mr. Ma Ping, Mr. Deng Jindong, Mr. Wen Deyong, Ms. Rong Yan and Mr. Wu Yijian; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Yu Tze Shan Hailson, Mr. Tan Wee Seng, Mr. Liu Zhengdong and Mr. Zhuo Fumin.

** The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name "Sinopharm Group Co. Ltd."*